Pancreatic Cancer Research

ResearcherWayne State UniversityNo recent work listed

Yiwei Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2389-3203; OpenAlex author ID A5100633410. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2011: 5 papers · 2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers

Papers 21

  1. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Co-author DOI 10.1002/ctm2.1513↗
  2. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Co-author DOI 10.1016/j.adro.2022.101122↗
  3. Connecting the Human Microbiome and Pancreatic Cancer. Co-author DOI 10.1007/s10555-022-10022-w↗
  4. Correction to: Connecting the human microbiome and pancreatic cancer. Co-author DOI 10.1007/s10555-022-10037-3↗
  5. Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer … Co-author DOI 10.1101/2022.03.08.481108↗
  6. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Co-author DOI 10.3390/cancers13164161↗
  7. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarc… First author DOI 10.1080/21541248.2017.1329694↗
  8. DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcin… First author DOI 10.3390/cancers11081101↗
  9. Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". Co-author DOI 10.1016/j.canlet.2018.03.020↗
  10. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. First author DOI 10.18632/oncotarget.19285↗
  11. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer. Co-author DOI 10.7150/ijbs.15017↗
  12. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Co-author DOI 10.1089/scd.2013.0551↗
  13. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Co-author DOI 10.1002/jcp.24162↗
  14. Pancreatic cancer stem cells: emerging target for designing novel therapy. Co-author DOI 10.1016/j.canlet.2012.03.018↗
  15. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Co-author DOI 10.1158/1940-6207.capr-11-0299↗
  16. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. Co-author DOI 10.1371/journal.pone.0050165↗
  17. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1002/jcb.23150↗
  18. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2011.03.012↗
  19. Pancreatic cancer: understanding and overcoming chemoresistance. First author DOI 10.1038/nrgastro.2010.188↗
  20. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. Co-author DOI 10.1371/journal.pone.0020537↗
  21. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Co-author PMID 21508353↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asfar Sohail Azmi · 19 shared papers, 2011–2023 · strength 1.50
  2. Amro Aboukameel · 10 shared papers, 2012–2023 · strength 1.05
  3. Philip A. Philip · 6 shared papers, 2017–2023 · strength 0.76
  4. Sahar F. Bannoura · 5 shared papers, 2022–2023 · strength 0.71
  5. Husain Yar Khan · 5 shared papers, 2022–2023 · strength 0.71
  6. Md. Hafiz Uddin · 4 shared papers, 2022–2023 · strength 0.54
  7. Fazlul H. Sarkar · 12 shared papers, 2011–2018 · strength 0.52
  8. Ramzi M. Mohammad · 5 shared papers, 2014–2021 · strength 0.49
  9. Rachel E. Sexton · 3 shared papers, 2022 · strength 0.40
  10. Bin Bao · 9 shared papers, 2011–2018 · strength 0.33
  11. Sanjeev Banerjee · 9 shared papers, 2011–2018 · strength 0.32
  12. Shadan S. Ali · 8 shared papers, 2011–2018 · strength 0.29
  13. Irfana Muqbil · 3 shared papers, 2017–2019 · strength 0.28
  14. Bayan A. Al-Share · 2 shared papers, 2022 · strength 0.27
  15. Bassel F. El‐Rayes · 2 shared papers, 2022 · strength 0.27
  16. Steve H. Kim · 2 shared papers, 2022–2023 · strength 0.27
  17. Anthony Frank Shields · 2 shared papers, 2022–2023 · strength 0.27
  18. Zhiwei Peter Wang · 6 shared papers, 2011–2018 · strength 0.22
  19. Lucio Miele · 5 shared papers, 2011–2018 · strength 0.18
  20. William Adrian Hall · 1 shared paper, 2023 · strength 0.17
  21. Susan Tsai · 1 shared paper, 2023 · strength 0.17
  22. Mandana Kamgar · 1 shared paper, 2023 · strength 0.17
  23. Tanya Odisho · 1 shared paper, 2023 · strength 0.14
  24. Ibrahim Hanna Azar · 1 shared paper, 2023 · strength 0.14
  25. Murray Korc · 2 shared papers, 2011–2013 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.